Immunologic status of patients with oral cancers: quantitation of helper and suppressor cells using monoclonal antibodies (Meeting abstract).

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Immunologic status of patients with oral cancers: quantitation of helper and suppressor cells using monoclonal antibodies (Meeting abstract).

Second International Congress on Oral Cancer. December 2-5, 1991, New Delhi, India, p. 49, 1991.. Unique Identifier : AIDSLINE ICDB/93686950
Thomas S; Nath I; Dhawan IK; University Coll. of Medical Sciences, Shahdara, Delhi, India

Abstract: Interest in an immunologic basis for the etiology, progression and treatment of malignant disease has prompted considerable investigation into the status of humoral and cellular immune mechanisms in cancer patients (pts). In this study, we have quantitated T cells and their subpopulations (helper and suppressor cells) by means of indirect immunofluorescence using monoclonal antibodies directed against phenotypic markers of functional T-cell subsets in pts with advanced malignancies of the oral cavity and healthy controls. The percentage of T cells was significantly lower in the pts when compared with the controls. The absolute numbers and the percentage of helper/inducer cell (OKT4+) in the pts and controls did not show any statistically significant difference. The significant finding in the present study was the increase in the percentage as well as in the absolute numbers of the OKT8+ suppressor/cytotoxic subset in the pt group. In terms of helper/suppressor ratio, there was a significant alteration in the pt group, with the helper/suppressor ratio being 1.3119 +/- 0.294 as compared with 1.9995 +/- 0.634 in the controls. In conclusion, the present study draws attention to an increase in T cells bearing the OKT8+ phenotypic markers of the suppressor/cytotoxic T-cell subset.

Keywords: Antibodies, Monoclonal/DIAGNOSTIC USE *CD4-CD8 Ratio Human Mouth Neoplasms/*IMMUNOLOGY T-Lymphocytes, Cytotoxic/PATHOLOGY T-Lymphocytes, Helper-Inducer/PATHOLOGY ABSTRACT
930228
M9320876

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .